{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:28:23Z","timestamp":1773095303000,"version":"3.50.1"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/bor.0000000000000281","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T16:46:08Z","timestamp":1458405968000},"page":"330-336","source":"Crossref","is-referenced-by-count":23,"title":["Vaccinations for rheumatoid arthritis"],"prefix":"10.1097","volume":"28","author":[{"given":"Marcia A.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis.","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R2-21-20210128","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/587063","article-title":"Vaccination in patients with chronic rheumatic or autoimmune diseases.","volume":"46","author":"Gluck","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R3-21-20210128","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis.","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R4-21-20210128","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/art.34530","article-title":"Development and validation of a risk score for serious infection in patients with rheumatoid arthritis.","volume":"64","author":"Crowson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R5-21-20210128","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor- antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"R6-21-20210128","doi-asserted-by":"crossref","first-page":"ofu024","DOI":"10.1093\/ofid\/ofu024","article-title":"Rates of pneumococcal disease in adults with chronic medical conditions.","volume":"1","author":"Shea","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"R7-21-20210128","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.vaccine.2015.01.065","article-title":"Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort.","volume":"33","author":"Hmamouchi","year":"2015","journal-title":"Vaccine"},{"key":"R8-21-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"R9-21-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.15585\/mmwr.mm6430a3","article-title":"Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season.","volume":"64","author":"Grohskopf","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R10-21-20210128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R11-21-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R12-21-20210128","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults.","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-21-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.","volume":"15","author":"Izurieta","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R14-21-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.","volume":"207","author":"Couch","year":"2013","journal-title":"J Infect Dis"},{"key":"R15-21-20210128","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","article-title":"TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.","volume":"51","author":"Franca","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R16-21-20210128","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1186\/ar3542","article-title":"Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with antitumor necrosis factor.","volume":"13","author":"Kobie","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R17-21-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza AH1N1 vaccination in patients with rheumatoid arthritis.","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R18-21-20210128","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.semarthrit.2008.12.002","article-title":"The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.","volume":"39","author":"Elkayam","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"R19-21-20210128","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clim.2009.09.014","article-title":"Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.","volume":"134","author":"Salemi","year":"2010","journal-title":"Clin Immunol"},{"key":"R20-21-20210128","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2007.077552","article-title":"The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination.","volume":"67","author":"Gelinck","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R21-21-20210128","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/art.30325","article-title":"Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.","volume":"63","author":"Gabay","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R22-21-20210128","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol"},{"key":"R23-21-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R24-21-20210128","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.130945","article-title":"Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.","volume":"41","author":"Kivitz","year":"2014","journal-title":"J Rheumatol"},{"key":"R25-21-20210128","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, antitumor necrosis factor , and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R26-21-20210128","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab.","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine"},{"key":"R27-21-20210128","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar3047","article-title":"Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.","volume":"12","author":"Rehnberg","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R28-21-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R29-21-20210128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R30-21-20210128","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","article-title":"Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis.","volume":"71","author":"Mori","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R32-21-20210128","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","article-title":"Protective effect of AH1N1 vaccination in immune-mediated disease: a prospectively controlled vaccination study.","volume":"51","author":"Adler","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R33-21-20210128","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R34-21-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R35-21-20210128","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"key":"R36-21-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semarthrit.2003.10.003","article-title":"The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.","volume":"33","author":"Elkayam","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R37-21-20210128","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202658","article-title":"Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy.","volume":"72","author":"Mori","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R38-21-20210128","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R39-21-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R40-21-20210128","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses.","volume":"72","author":"Salinas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R41-21-20210128","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease.","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R42-21-20210128","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s10067-011-1856-5","article-title":"Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.","volume":"30","author":"Kapetanovic","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R43-21-20210128","doi-asserted-by":"crossref","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R44-21-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R45-21-20210128","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database.","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"key":"R46-21-20210128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R47-21-20210128","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/infdis\/jit182","article-title":"Safety of zoster vaccine in elderly adults following documented herpes zoster.","volume":"208","author":"Morrison","year":"2013","journal-title":"J Infect Dis"},{"key":"R48-21-20210128","first-page":"729","article-title":"Centers for Disease Control and Prevention CDC. Update on recommendations for use of herpes zoster vaccine.","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R49-21-20210128","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"R50-21-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R51-21-20210128","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R52-21-20210128","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R53-21-20210128","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/annrheumdis-2013-204993","article-title":"Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.","volume":"74","author":"Kim","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R54-21-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","article-title":"Higher incidence of abnormal Pap smears in women with inflammatory bowel disease.","volume":"103","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R55-21-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10067-010-1606-0","article-title":"Systemic lupus erythematosus, human papillomavirus infection, cervical premalignant and malignant lesions: a systematic review.","volume":"30","author":"Santana","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R56-21-20210128","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1002\/art.30483","article-title":"High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.","volume":"63","author":"Dreyer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R57-21-20210128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","article-title":"Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature.","volume":"13","author":"Zard","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R58-21-20210128","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/annrheumdis-2013-203429","article-title":"Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.","volume":"73","author":"Heijstek","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R59-21-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.","volume":"72","author":"Mok","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R60-21-20210128","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1016\/j.vaccine.2015.05.041","article-title":"Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: a systematic review.","volume":"33","author":"Pellegrino","year":"2015","journal-title":"Vaccine"},{"key":"R61-21-20210128","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"R62-21-20210128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4254\/wjh.v7.i3.344","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs.","volume":"7","author":"Nard","year":"2015","journal-title":"World J Hepatol"},{"key":"R63-21-20210128","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10067-012-1960-1","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF agents: a retrospective analysis of 49 cases.","volume":"31","author":"Ryu","year":"2012","journal-title":"Clin Rheumatol"},{"key":"R64-21-20210128","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","article-title":"Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations.","volume":"21","author":"Mori","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R65-21-20210128","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.","volume":"90","author":"Perez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"R66-21-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","article-title":"Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.","volume":"29","author":"Carroll","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R67-21-20210128","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-012-1988-2","article-title":"Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.","volume":"31","author":"Tan","year":"2012","journal-title":"Clin Rheumatol"},{"key":"R68-21-20210128","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"R69-21-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.","volume":"89","author":"Pei","year":"2010","journal-title":"Ann Hematol"},{"key":"R70-21-20210128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009.","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"R71-21-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-150-2-200901200-00100","article-title":"National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.","volume":"150","author":"Sorrell","year":"2009","journal-title":"Ann Intern Med"},{"key":"R72-21-20210128","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"R73-21-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R74-21-20210128","first-page":"1","article-title":"Centers for Disease Control and Prevention CDC. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R75-21-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.38960","article-title":"Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.","volume":"67","author":"Oliveira","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R76-21-20210128","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/acr.20045","article-title":"Yellow fever revaccination during infliximab therapy.","volume":"62","author":"Scheinberg","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R77-21-20210128","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/acr.22021","article-title":"Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study.","volume":"65","author":"Kerneis","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R78-21-20210128","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:35:01Z","timestamp":1620948901000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201605000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000281","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}